Brand-name prescription drug pricing [electronic resource] : lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases : report to congressionals requesters.
Imprint
[Washington, D.C.] : U.S. Govt. Accountability Office, [2009]
Brand name prescription drug pricing : lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases
Lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases
